Prestige Consumer Healthcare (PBH) Expected to Announce Earnings on Thursday

Key Points

• Prestige Consumer Healthcare is set to release its Q1 2026 earnings data on August 7th, expecting earnings of $1.01 per share and revenue of $260.71 million.
• In its last quarterly earnings report, Prestige reported $1.32 EPS, exceeding estimates and showing a 7.0% year-over-year revenue increase.
• Institutional investors hold 99.95% of Prestige’s stock, with several hedge funds increasing their stakes significantly in the past quarter.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) is expected to issue its Q1 2026 quarterly earnings data before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of $1.01 per share and revenue of $260.71 million for the quarter. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.700-4.820 EPS.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $1.32 EPS for the quarter, beating the consensus estimate of $1.30 by $0.02. Prestige Consumer Healthcare had a net margin of 18.86% and a return on equity of 12.87%. The business had revenue of $296.52 million for the quarter, compared to analysts' expectations of $289.36 million. During the same period in the prior year, the firm earned $1.02 earnings per share. Prestige Consumer Healthcare's revenue was up 7.0% compared to the same quarter last year. On average, analysts expect Prestige Consumer Healthcare to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Prestige Consumer Healthcare Price Performance

Shares of PBH traded down $0.22 during mid-day trading on Friday, hitting $73.73. 423,917 shares of the company traded hands, compared to its average volume of 406,596. Prestige Consumer Healthcare has a one year low of $64.94 and a one year high of $90.04. The company has a current ratio of 4.20, a quick ratio of 2.82 and a debt-to-equity ratio of 0.55. The business has a 50-day moving average of $80.89 and a 200 day moving average of $82.28. The stock has a market capitalization of $3.64 billion, a price-to-earnings ratio of 17.19, a PEG ratio of 2.22 and a beta of 0.43.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Wall Street Zen raised shares of Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a report on Saturday, July 5th. Royal Bank Of Canada raised shares of Prestige Consumer Healthcare to a "hold" rating in a report on Thursday, May 8th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $93.33.

Hedge Funds Weigh In On Prestige Consumer Healthcare

A number of hedge funds and other institutional investors have recently made changes to their positions in PBH. AQR Capital Management LLC boosted its position in shares of Prestige Consumer Healthcare by 11.9% during the first quarter. AQR Capital Management LLC now owns 30,056 shares of the company's stock worth $2,558,000 after purchasing an additional 3,200 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Prestige Consumer Healthcare by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,490 shares of the company's stock worth $2,535,000 after purchasing an additional 1,289 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Prestige Consumer Healthcare by 28.4% during the first quarter. Goldman Sachs Group Inc. now owns 546,672 shares of the company's stock worth $46,997,000 after purchasing an additional 120,965 shares in the last quarter. Jane Street Group LLC boosted its position in shares of Prestige Consumer Healthcare by 204.0% during the first quarter. Jane Street Group LLC now owns 104,802 shares of the company's stock worth $9,010,000 after purchasing an additional 70,330 shares in the last quarter. Finally, Geneos Wealth Management Inc. boosted its position in shares of Prestige Consumer Healthcare by 92.8% during the first quarter. Geneos Wealth Management Inc. now owns 559 shares of the company's stock worth $48,000 after purchasing an additional 269 shares in the last quarter. 99.95% of the stock is owned by institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.